Patents Assigned to Pfizer
  • Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
    Publication number: 20020147206
    Abstract: The present invention relates to a method of treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal by administering to the mammal a neurotransmitter-inducing or precursor agent in combination with an (SRI) antidepressant or an anxiolytic agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a neurotransmitter-inducing or precursor agent, and an SRI antidepressant or anxiolytic agent.
    Type: Application
    Filed: December 19, 2001
    Publication date: October 10, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry R. Howard
  • Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
    Patent number: 6462048
    Abstract: The present invention relates to lactam derivatives of the formula wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for their preparation, and to their medicinal use as selective agonists and antagonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1D receptors. These compounds are useful in treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard
  • Aryl fused azapolycyclic compounds
    Patent number: 6462035
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventor: Jotham Wadsworth Coe
  • Dual-tagged proteins and their uses
    Patent number: 6462254
    Abstract: The present invention provides improved methods for detection of recombinant proteins. The fusion proteins of the invention comprise a capture tag sequence, a detection tag sequence, and polypeptide sequence of interest.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: October 8, 2002
    Assignees: Valentis, Inc., Pfizer, Inc.
    Inventors: John Vernachio, Jackie Papkoff
  • Razor system with worn blade indicator
    Patent number: 6460251
    Abstract: The present invention is directed to a wet shaving system having an electronic indicator for indicating when the blades are becoming dull and in need of replacement. As razor blades dull, the user must exert greater force during shaving to achieve a satisfactory shave. Upon exertion of this extra force, a piston which is adjacent to the blades moves away from the blades in response to the increased forces encountered by the blades during shaving. Upon moving a sufficient distance, the piston pushes into an electronic device, such as a potentiometer, which initiates a signal processing circuit which in turn activates an indicator, such as a light-emitting diode. The activation of the indicator is a signal to the user to replace the blades.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventor: Glennis J. Orloff
  • Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines
    Patent number: 6461822
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventors: Christopher A. Gabel, Richard J. Griffiths, James F. Eggler, Mark A. Dombroski, Kieran Geoghegan
  • Antiparasitic formulation
    Publication number: 20020142972
    Abstract: Long-acting antiparasitic formulations of doramectin, suitable for injection, are described herein.
    Type: Application
    Filed: November 7, 2001
    Publication date: October 3, 2002
    Applicant: Pfizer Inc.
    Inventors: Stephen Richard Wicks, Timothy Michael Lukas, Valerie Denise Harding, Snezana Milojevic
  • Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
    Patent number: 6458951
    Abstract: Compounds of the formulae (IA) and (IB): wherein R1 is C1 to C3 alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1 to C4 alkoxy; halo; CN; CF3; OCF3 or C1 to C4 alkyl wherein said C1 to C4 alkyl group is optionally substituted by C1 to C4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2 is C1 to C6 alkyl and R13 is OR3 or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: October 1, 2002
    Assignee: Pfizer Inc
    Inventors: Mark Edward Bunnage, John Paul Mathias, Stephen Derek Albert Street, Anthony Wood
  • 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
    Patent number: 6458822
    Abstract: The present invention relates to a compound of the formula wherein R1, R2, R3 and R4 are as defined above, and pharmaceutically acceptable salts and solvates thereof, that are useful, for example, as matrix metalloproteinase inhibitors. The present invention is also directed to pharmaceutical compositions comprising such compounds and methods of treatment for diseases such as osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, tissue ulceration, restinosis, periodontal disease, inflammation, epidermolysis bullosa, scleritis, stroke, Alzheimer's disease, and the like, characterized by inappropriate matrix metalloproteinase activity. Processes for the synthesis of compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: October 1, 2002
    Assignee: Pfizer Inc.
    Inventors: Ralph P. Robinson, Ellen R. Laird
  • Method of treatment
    Patent number: 6455567
    Abstract: The invention provides the use of a compound of formula (I) wherein R1 and R2 independently represent H or C1-C6 alkyl, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of dermatological disorders; peripheral neuropathies; arthritis; gastrointestinal or urogenital diseases; headache associated with substances or their withdrawal; tension headache; pediatric migraine; post-traumatic dysautonomic cephalgia; orofacial pain; allergic or chronic obstructive airways diseases; glaucoma or ocular inflammation; or prophylaxis of migraine.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: September 24, 2002
    Assignee: Pfizer Inc.
    Inventors: Kathryn Louise Monkhouse, Paul Gupta, Shirley Jones, Juan Lahuerta, Gillian Christine Land, Susan Frances Robson, Gillian Mary Samuels, Alan Brian Wilson, Martin James Wythes
  • Therapeutic combination
    Patent number: 6455574
    Abstract: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: September 24, 2002
    Assignee: Pfizer Inc.
    Inventor: Jan Buch
  • Estrogen agonist/antagonist metabolites
    Patent number: 6455572
    Abstract: This invention relates to compounds that are mammalian metabolites of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compositions for the treatment of disease and methods of treating disease.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: September 24, 2002
    Assignee: Pfizer Inc.
    Inventors: Wesley W. Day, Kim A. Johnson, Chandra A. Prakash, James F. Eggler
  • Histamine receptor antagonists
    Publication number: 20020132755
    Abstract: The present invention provides a combination of (a) a histamine H1 receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H4 receptor as compared to the histamine H3 receptor; and an antagonist that is at least 10-fold selective for the histamine H4 receptor as compared to the histamine H3 receptor: and compositions and uses thereof.
    Type: Application
    Filed: January 17, 2002
    Publication date: September 19, 2002
    Applicant: Pfizer Inc.
    Inventors: Stephen Jenkinson, Mark Anthony O'Reilly, Michael Andrew Trevethick
  • Treatments for obesity and methods for identifying compounds useful for treating obesity
    Patent number: 6451783
    Abstract: The present invention provides a method of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia, hypertriglyceridemia, or substance abuse, the method comprising the step of administering to a patent having or at risk of having one of the above-mentioned diseases a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of &agr;-melanocyte stimulating hormone to melanocortin receptors.
    Type: Grant
    Filed: January 16, 2001
    Date of Patent: September 17, 2002
    Assignee: Pfizer Inc.
    Inventors: John R. Hadcock, Andrew G. Swick
  • N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders
    Patent number: 6451803
    Abstract: This invention relates to the use of a compound of the formula wherein m, R1, R2, R3, R4, R5 and X are as defined in the disclosure, for treating or preventing migraine, depression and other disorders for which a 5-HT1 agonist or antagonist is indicated.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: September 17, 2002
    Assignee: Pfizer INC
    Inventor: Harry R. Howard
  • Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
    Patent number: 6451587
    Abstract: The present invention relates to microbial processes for carrying out the asymmetric reduction of a ketone to an alcohol, which comprises: contacting the ketone with a microorganism, or an enzyme reduction system capable of accomplishing the subject reduction comprising an enzyme derived from said microorganism and a co-factor for said enzyme, and incubating the resulting mixture under conditions sufficient to yield more of the desired (R)-enantiomer of the corresponding alcohol than the undesired (S)-enantiomer. The chiral (R)-enantiomer can be used in the synthesis of certain &bgr;-adrenergic receptor agonists.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: September 17, 2002
    Assignee: Pfizer Inc.
    Inventors: Michael P. Burns, John W. Wong
  • Olefination process to itaconate and succinate derivatives
    Patent number: 6452041
    Abstract: An efficient and selective process, capable of scale-up, to make itaconate derivatives of formula (IV), and/or succinate derivatives of formula (V) and/or (VI) by asymmetric hydrogenation of the itaconate derivatives. wherein R, R1 and R2 are as defined herein.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: September 17, 2002
    Assignee: Pfizer Inc.
    Inventors: Andrew Michael Derrick, Nicholas Murray Thomson
  • N-benzenesulfonyl l-proline compounds as bradykinin antagonists
    Publication number: 20020128271
    Abstract: This invention provides a compound of the formula (I): 1
    Type: Application
    Filed: December 5, 2001
    Publication date: September 12, 2002
    Applicant: Pfizer Inc.
    Inventors: Yasuhiro Katsu, Makoto Kawai, Hiroki Koike, Seiji Nukui
  • Treatment of insulin resistance with growth hormone secretagogues
    Patent number: 6448263
    Abstract: This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: September 10, 2002
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Charles Kwok-Fung Chiu, Lydia Codetta Pan, Bruce Allen Lefker, Judith Lee Treadway, Michael Paul Zawistoski
  • Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
    Patent number: 6448265
    Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: September 10, 2002
    Assignee: Pfizer, Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.